Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer

Thyroid cancer is the most common (~90%) type of endocrine-system tumor, accounting for 70% of the deaths from endocrine cancers. In the last years, the high-throughput genomics has been able to identify pathways/molecular targets involved in survival and tumor progression. Targeted therapy and immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragusa, Francesca, Ferrari, Silvia Martina, Elia, Giusy, Paparo, Sabrina Rosaria, Balestri, Eugenia, Botrini, Chiara, Patrizio, Armando, Mazzi, Valeria, Guglielmi, Giovanni, Foddis, Rudy, Spinelli, Claudio, Ulisse, Salvatore, Antonelli, Alessandro, Fallahi, Poupak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144613/
https://www.ncbi.nlm.nih.gov/pubmed/35628540
http://dx.doi.org/10.3390/ijms23105731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144613/
https://www.ncbi.nlm.nih.gov/pubmed/35628540
http://dx.doi.org/10.3390/ijms23105731

Ejemplares similares